Patent details

Basic Information

Publication number:

EP3762397

PCT Application Number:

US2019021145

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP197124407

PCT Publication Number:

WO2019173587

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

French Title of Invention:

DINUCLÉOTIDES CYCLIQUES EN TANT QU'AGENTS ANTICANCÉREUX

German Title of Invention:

CYCLISCHE DINUKLEOTIDE ALS ANTIKREBSMITTEL

SPC Number:

Dates

Filing date:

07/03/2019

Grant date:

01/05/2024

EP Publication Date:

13/01/2021

PCT Publication Date:

12/09/2019

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

01/05/2024

EP B1 Publication Date:

01/05/2024

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

07/03/2039

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

24/04/2024

 

 

Name:

Bristol-Myers Squibb Company

Address:

Route 206 and Province Line Road, Princeton, NJ 08543, United States (US)

Inventor

1

Name:

FINK, Brian E.

Address:

United States (US)

2

Name:

RUAN, Zheming

Address:

United States (US)

Priority

Priority Number:

201862640325 P

Priority Date:

08/03/2018

Priority Country:

United States (US)

Classification

IPC classification:

C07H 21/02; A61P 35/00;

Publication

European Patent Bulletin

Issue number:

202418

Publication date:

01/05/2024

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

30/09/2025

Annual Fee Number:

7

Annual Fee Amount:

82 Euro

Penalty Fee Amount:

20 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages